AI English summary of an SEC filing — figures as filed
Insulet PODDThe company said total revenue for the 3 months ended June 30, 2024 increased $92.0 million, or 23.2%, from $396.5 million a year earlier to $488.5 million. It cited higher volume from a growing customer base as the driver of the increase.
Key points
AI summaryThe company said total revenue for the 3 months ended June 30, 2024 increased $92.0 million, or 23.2%, from $396.5 million a year earlier to $488.5 million. It cited higher volume from a growing customer base as the driver of the increase.
The company said gross margin for Q2 2024 was 67.7%, up 90 basis points from 66.8% a year earlier. It said the $13.5 million charge related to the discontinuation of Omnipod GO partly offset this improvement.
The company said its effective tax rate was a tax benefit of 269.2% and 126.6% for the 3 months and 6 months ended 2024, respectively. It said the non-cash tax benefit from the release of most of its valuation allowance against deferred tax assets was $146.9 million for the 3 months and $153.5 million for the 6 months.
The company said net cash provided by operating activities was $184.1 million for the 6 months ended June 30, 2024. Capital expenditures for the same period were $44.6 million, compared with $26.2 million a year earlier, and the company said they were mainly for equipment purchases to expand manufacturing capacity.
Key figures
Quarter ended June 30, 2024
- Revenue
- $488M
- Operating income
- $55M
- Net income
- $189M
- EPS
- $2.59
- Gross profit
- $331M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q2 2024 Total Revenue $488.5 million
The company said total revenue for the 3 months ended June 30, 2024 increased $92.0 million, or 23.2%, from $396.5 million a year earlier to $488.5 million. It cited higher volume from a growing customer base as the driver of the increase.
Source · Based on the MD&A text of the filing
Q2 Gross Margin 67.7% and Omnipod GO Costs
The company said gross margin for Q2 2024 was 67.7%, up 90 basis points from 66.8% a year earlier. It said the $13.5 million charge related to the discontinuation of Omnipod GO partly offset this improvement.
Source · Based on the MD&A text of the filing
Tax Benefit and Valuation Allowance Release
The company said its effective tax rate was a tax benefit of 269.2% and 126.6% for the 3 months and 6 months ended 2024, respectively. It said the non-cash tax benefit from the release of most of its valuation allowance against deferred tax assets was $146.9 million for the 3 months and $153.5 million for the 6 months.
Source · Based on the MD&A text of the filing
6-Month Operating Cash Flow and Capital Expenditures
The company said net cash provided by operating activities was $184.1 million for the 6 months ended June 30, 2024. Capital expenditures for the same period were $44.6 million, compared with $26.2 million a year earlier, and the company said they were mainly for equipment purchases to expand manufacturing capacity.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…